Agile Therapeutics (NASDAQ:AGRX) – Equities researchers at Zacks Investment Research dropped their FY2018 earnings per share estimates for Agile Therapeutics in a research note issued on Monday, May 14th. Zacks Investment Research analyst D. Bautz now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.80) for the year, down from their previous estimate of ($0.74).
A number of other analysts have also recently issued reports on the stock. HC Wainwright set a $8.00 target price on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 9th. ValuEngine upgraded shares of Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Finally, Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a research report on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $9.00.
Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Monday, March 12th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05.
A number of hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC bought a new position in Agile Therapeutics in the 4th quarter valued at about $9,092,000. Franklin Resources Inc. increased its holdings in Agile Therapeutics by 17.0% in the 1st quarter. Franklin Resources Inc. now owns 3,355,200 shares of the specialty pharmaceutical company’s stock valued at $8,623,000 after buying an additional 487,400 shares during the period. Renaissance Technologies LLC increased its holdings in Agile Therapeutics by 313.7% in the 4th quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock valued at $985,000 after buying an additional 277,600 shares during the period. Broadfin Capital LLC bought a new position in Agile Therapeutics in the 4th quarter valued at about $964,000. Finally, Dimensional Fund Advisors LP increased its holdings in Agile Therapeutics by 62.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after buying an additional 55,937 shares during the period. 70.84% of the stock is currently owned by hedge funds and other institutional investors.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.